Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer
Saved in:
Main Authors: | Martin Stockler, Yu Yang Soon, Chee Khoon Lee, Teng Hwee Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | BMJ Oncology |
Online Access: | https://bmjoncology.bmj.com/content/3/1/e000227.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
by: Chi Nguyen, et al.
Published: (2023-01-01) -
Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors
by: Xiaoping Li, et al.
Published: (2025-01-01) -
YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
by: Ling-Chen Li, et al.
Published: (2023-01-01) -
Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01) -
Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
by: Tadahiro Kuribayashi, et al.
Published: (2025-01-01)